AceCounter
contents footer
  1. HOME
  2. All KODEX ETFs
  3. Product Details

Foreign Equity

KODEX SYNTH-US Biotech(185680)

The most effective way to invest in the fast-growing industry, Biotechnology.
KODEX Synth-US bio mainly focuses on USA's biotechnology companies committed to healthier future.

Last data obtained Quotes delayed at least 20 minutes. Market data provided by KOSCOM.

  • Current Price (KRW)

    21,945

    up 235 (1.08%)

  • iNAV (KRW)

    21,918

    up 266 (1.23%)

  • Trading Volume (shares)

    483

About Product

* as of Nov 15, 2019

Benchmark Index

S&P Biotechnology Select Industry Index(KRW)

The S&P Biotechnology Select Sector Index seeks to track the Biotechnology sector - stock classifications are based on the Global Industry Classification Standard (GICS).

View index information in detail

Key Facts

Basic Information - Net Assets, Benchmark Index, Gross Expense Ratio, Dividend, Benchmark Index, Base Currency, General Administrator, Trustee
Net Assets 11 (billion) Base Currency KRW
Inception Date October 31, 2013 General
Administrator
KSD
Gross Expense
Ratio
0.250%
(AP : 0.020%, Manager fee : 0.190%, Trustee Fee : 0.020%, General Administrator Fee : 0.020%)
Trustee KB Bank
Dividend Annual dividend distribution, only if applicable.
(Such funds mainly investing in derivative products and/or re-investing any dividend payouts often do not distribute dividends.)
Related
Documents
-
  • Carefully consider the Funds' investment objectives, risk factors, and charges and expenses before investing.
  • Collective investment schemes are not insured by the Korea Deposit Insurance Corporation.
  • The performance quoted represents past performance and does not guarantee future results.
  • Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold.
  • Current performance may be lower or higher than the performance quoted.
  • This information is not warranted to be accurate, complete, or timely.
  • Neither KOSCOM nor Samsung Asset Management is responsible for any damages or losses arising from any use of the information on this website.
  • This website is made in the Korean language, and if there shall arise any conflict between the Korean version and any translation thereof,
    including this -English translation, the Korean version shall prevail.

Samsung Asset Managementcompliance review No.2018-189 (2018.05.21)